Fas Ligand/TNFSF6 Antibody [Unconjugated]

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Fas Ligand (FasL), also known as CD178, CD95L, or TNFSF6, is a 40 kDa type II transmembrane member of the TNF superfamily of proteins. Its ability to induce apoptosis in target cells plays an important role in the development, homeostasis, and function of the immune system (1). Mature human Fas Ligand consists of a 179 amino acid (aa) extracellular domain (ECD), a 22 aa transmembrane segment, and a 80 aa cytoplasmic domain (2). Within the ECD, human Fas Ligand shares 81% and 78% aa sequence identity with mouse and rat Fas Ligand, respectively. Both mouse and human Fas Ligand are active on mouse and human cells (2, 3). Fas Ligand is expressed on the cell surface as a nondisulfide-linked homotrimer on activated CD4⁺ Th1 cells, CD8⁺ cytotoxic T cells, and NK cells (1). Fas Ligand binding to Fas/CD95 on an adjacent cell triggers apoptosis in the Fas‑expressing cell (2, 4). Fas Ligand also binds DcR3 which is a soluble decoy receptor that interferes with Fas Ligand-induced apoptosis (5). Fas Ligand can be released from the cell surface by metalloproteinases as a 26 kDa soluble molecule which remains trimeric (6, 7). Shed Fas Ligand retains the ability to bind Fas, although its ability to trigger apoptosis is dramatically reduced (6, 7). In the absence of TGF‑ beta , however, Fas Ligand/Fas interactions instead promote neutrophil-mediated inflammatory responses (3, 8). Fas Ligand itself transmits reverse signals that costimulate the proliferation of freshly antigen-stimulated T cells (9). Fas Ligand-induced apoptosis plays a central role in the development of immune tolerance and the maintance of immune privileged sites (10). This function is exploited by tumor cells which evade immune surveillance by upregulating Fas Ligand to kill tumor infiltrating lymphocytes (8, 11). In gld mice, a Fas Ligand point mutation is the cause of severe lymphoproliferation and systemic autoimmunity (12, 13).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 5 applications: Bioassay, Flow Cytometry, ICC, Neutralization, Western Blot.

Showing Publications 1 - 7 of 7.

Publications using AF126	Applications	Species
WR English, H Ireland-Ze, AH Baker, TD Littlewood, MR Bennett, G Murphy Tissue Inhibitor of Metalloproteinase-3 (TIMP-3) induces FAS dependent apoptosis in human vascular smooth muscle cells PLoS ONE, 2018-04-04;13(4):e0195116. 2018-04-04 [PMID: 29617412] (Flow Cytometry, Neutralization, Western Blot, Human)	Flow Cytometry, Neutralization, Western Blot	Human
Tushar Piyush, Jonathan M Rhodes, Lu-Gang Yu MUC1 O-glycosylation contributes to anoikis resistance in epithelial cancer cells Cell Death Discovery 7/17/2017 [PMID: 28725490]
Q Zhao, T Piyush, C Chen, M A Hollingsworth, J Hilkens, J M Rhodes et al. MUC1 extracellular domain confers resistance of epithelial cancer cells to anoikis Cell Death & Disease 10/2/2014 [PMID: 25275599]
Siewiera J, El Costa H, Tabiasco J, Berrebi A, Cartron G, Le Bouteiller P, Jabrane-Ferrat N Human cytomegalovirus infection elicits new decidual natural killer cell effector functions. PLoS Pathog, 2013-04-04;9(4):e1003257. 2013-04-04 [PMID: 23592985] (Bioassay, Human)	Bioassay	Human
Beynon V, Quintana FJ, Weiner HL Activated Human CD4+CD45RO+ Memory T-Cells Indirectly Inhibit NLRP3 Inflammasome Activation through Downregulation of P2X7R Signalling. PLoS ONE, 2012-06-29;7(6):e39576. 2012-06-29 [PMID: 22768094] (Neutralization, Human)	Neutralization	Human
Kim YC, Kim BG, Lee JH Thymosin beta10 expression driven by the human TERT promoter induces ovarian cancer-specific apoptosis through ROS production. PLoS ONE, 2012-05-18;7(5):e35399. 2012-05-18 [PMID: 22623951] (ICC, Western Blot, Human)	ICC, Western Blot	Human
Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J. Allergy Clin. Immunol., 2005-08-19;116(4):923-4. 2005-08-19 [PMID: 16210071] (Neutralization, Human)	Neutralization	Human

Array AF126

• Fas Ligand/TNFSF6 Antibodies
• Fas Ligand/TNFSF6 ELISA Kits
• Fas Ligand/TNFSF6 Lysate
• Fas Ligand/TNFSF6 Protein
• Fas Ligand/TNFSF6 Proteins and Enzymes
• Fas Ligand/TNFSF6 ELISAs